Financial Contrast: Daiichi Sankyo (OTCMKTS:DSNKY) versus Lifecore Biomedical (NASDAQ:LFCR)

Lifecore Biomedical (NASDAQ:LFCR) and Daiichi Sankyo (OTCMKTS:DSNKY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Lifecore Biomedical and Daiichi Sankyo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Daiichi Sankyo	10.92%	14.35%	6.10%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lifecore Biomedical and Daiichi Sankyo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1	4	0	0	1.80
Daiichi Sankyo	1	1	0	0	1.50

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential downside of 0.31%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Lifecore Biomedical is more favorable than Daiichi Sankyo.

Volatility & Risk

Lifecore Biomedical has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Daiichi Sankyo has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lifecore Biomedical and Daiichi Sankyo”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87 million	1.91	-$40.50 million	($1.07)	-6.09
Daiichi Sankyo	$14.10 billion	2.19	$1.72 billion	$0.86	19.26

Daiichi Sankyo has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.

Summary

Daiichi Sankyo beats Lifecore Biomedical on 8 of the 13 factors compared between the two stocks.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.